Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC (CM816) Better in terms of pCR, 3y-EFS, and OS BUT The rate of surgery cancellations due to early progression is 16%. ( Nivo+ChT: 6.7%). While pseudoprogression is a factor, such high early progression rates may prevent Nivo+Ipi from routine use.”
Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, and Mariano Provencio Pulla.
